AcelRx Pharmaceuticals Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AcelRx Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACRX, but not buy additional shares or sell existing shares.
View analyst ratings for AcelRx Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given AcelRx Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AcelRx Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

AcelRx Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 11,850,000 shares, an increase of 46.5% from the March 15th total of 8,090,000 shares. Based on an average daily volume of 6,020,000 shares, the short-interest ratio is currently 2.0 days.
View AcelRx Pharmaceuticals' Short Interest.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) issued its quarterly earnings data on Sunday, March, 14th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, hitting analysts' consensus estimates of ($0.10). The specialty pharmaceutical company earned $0.74 million during the quarter, compared to analyst estimates of $0.75 million.
View AcelRx Pharmaceuticals' earnings history.

AcelRx Pharmaceuticals' stock was trading at $1.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ACRX shares have decreased by 8.2% and is now trading at $1.12.
View which stocks have been most impacted by COVID-19.

2 brokerages have issued 1-year price objectives for AcelRx Pharmaceuticals' shares. Their forecasts range from $0.84 to $8.00. On average, they expect AcelRx Pharmaceuticals' stock price to reach $4.42 in the next year. This suggests a possible upside of 294.6% from the stock's current price.
View analysts' price targets for AcelRx Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to AcelRx Pharmaceuticals include CytomX Therapeutics (CTMX), XBiotech (XBIT), Evelo Biosciences (EVLO), Eagle Pharmaceuticals (EGRX), SIGA Technologies (SIGA), Akebia Therapeutics (AKBA), Verastem (VSTM), 89bio (ETNB), Molecular Templates (MTEM), Altimmune (ALT), Catalyst Pharmaceuticals (CPRX), Spectrum Pharmaceuticals (SPPI), Avadel Pharmaceuticals (AVDL), Neoleukin Therapeutics (NLTX) and Viking Therapeutics (VKTX).
View all of ACRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

AcelRx Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.39%), GSA Capital Partners LLP (0.16%), The Manufacturers Life Insurance Company (0.05%), Exane Derivatives (0.05%), American International Group Inc. (0.05%) and BNP Paribas Arbitrage SA (0.03%). Company insiders that own AcelRx Pharmaceuticals stock include Adrian Adams, Mark G Edwards and Vincent J Angotti.
View institutional ownership trends for AcelRx Pharmaceuticals.

ACRX stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP.
View insider buying and selling activity for AcelRx Pharmaceuticals or view top insider-selling stocks.

ACRX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., The Manufacturers Life Insurance Company , Exane Derivatives, BNP Paribas Arbitrage SA, and American International Group Inc.. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Adrian Adams, Mark G Edwards, and Vincent J Angotti.
View insider buying and selling activity for AcelRx Pharmaceuticals or or view top insider-buying stocks.

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACRX stock can currently be purchased for approximately $1.12.

AcelRx Pharmaceuticals has a market capitalization of $133.40 million and generates $2.29 million in revenue each year. The specialty pharmaceutical company earns $-53,240,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis.

AcelRx Pharmaceuticals employs 54 workers across the globe.

The official website for AcelRx Pharmaceuticals is www.acelrx.com.

AcelRx Pharmaceuticals is headquartered at 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063.

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]